In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will receive oral ruxolitinib and ABBV-744 is going to be specified as "add-on" therapy. https://dallasujxjx.blogocial.com/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described-67946015